Literature DB >> 31009585

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.

Motoaki Sano1, Shinichi Goto1.   

Abstract

Entities:  

Keywords:  cell transdifferentiation; heart failure; hematocrit; hypoxia; sodium-potassium pump; sympathetic nervous system

Mesh：

Substances：

Year:  2019        PMID： 31009585     DOI： 10.1161/CIRCULATIONAHA.118.038881

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  46 in total

1.  Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.

Authors:  Ahmed A Kolkailah; Stephen D Wiviott; Itamar Raz; Sabina A Murphy; Ofri Mosenzon; Deepak L Bhatt; Lawrence A Leiter; John P H Wilding; Ingrid Gause-Nilsson; Marc S Sabatine; Darren K McGuire
Journal:  Diabetes Care       Date:  2022-02-01       Impact factor: 19.112

Review 2.  Kidney and heart failure outcomes associated with SGLT2 inhibitor use.

Authors:  Annemarie B van der Aart-van der Beek; Rudolf A de Boer; Hiddo J L Heerspink
Journal:  Nat Rev Nephrol       Date:  2022-02-10       Impact factor: 28.314

Review 3.  Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.

Authors:  Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim
Journal:  J Cardiovasc Transl Res       Date:  2022-03-15       Impact factor: 4.132

4.  Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.

Authors:  Kenichi Katsurada; Shyam S Nandi; Neeru M Sharma; Kaushik P Patel
Journal:  Circ Heart Fail       Date:  2021-11-18       Impact factor: 8.790

Review 5.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

Review 6.  Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors.

Authors:  Cezary Wojcik; Bruce A Warden
Journal:  Curr Cardiol Rep       Date:  2019-09-14       Impact factor: 2.931

7.  Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients.

Authors:  Minkook Son; Ye Sung Lee; A Ram Hong; Jee Hee Yoon; Hee Kyung Kim; Ho-Cheol Kang; Sung Yang
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-04       Impact factor: 3.727

Review 8.  Estimated plasma volume status in heart failure: clinical implications and future directions.

Authors:  Masatake Kobayashi; Nicolas Girerd; Kevin Duarte; Tahar Chouihed; Taishiro Chikamori; Bertram Pitt; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2021-01-06       Impact factor: 5.460

9.  Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.

Authors:  Atsushi Tanaka; Michio Shimabukuro; Hiroki Teragawa; Yosuke Okada; Toshinari Takamura; Isao Taguchi; Shigeru Toyoda; Hirofumi Tomiyama; Shinichiro Ueda; Yukihito Higashi; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-06-28       Impact factor: 9.951

10.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic
Journal:  Diabetes       Date:  2020-10-26       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.